Methods and Pharmaceutical Compositions Using Orexins (OXA, OXB) for the Treatment of Prostate Cancers
AssigneesInserm (Institut National De La Sante Et De La Recherche Medicale), Universite De Rouen, Universite Paris Diderot—Paris 7
InventorsNicolas Chartrel, Youssef Anouar, Lydie Jeandel, David Alexandre, Jerome Leprince, Alain Couvineau, Thierry Voisin
Life of this patent
Estimating the term…
Abstract
The present disclosure relates to methods and pharmaceutical compositions for the treatment of prostate cancers. In particular, the present invention relates to an OX1R agonist for use in the treatment of prostate cancer in a subject in need thereof.
Claims14
A method for the treatment of prostate cancer in a subject in need thereof comprising administering the subject with a therapeutically effective amount of a OX1R agonist.
A method for treating a prostate cancer in a subject in need thereof comprising the steps consisting of i) determining the expression level of OX1R in a tumour tissue sample obtained from the subject, ii) comparing the expression level determined at step i) with a reference value and iii) administering the subject with a therapeutically effective amount of an OX1R agonist when the level determined at step i) is higher than the reference value.
A method for screening a drug for the treatment of prostate cancer comprising the steps of i) providing a plurality of test substances ii) determining whether the test substances are OX1R agonists and iii) positively selecting the test substances that are OX1R agonists.
Dependencies are inferred from the claim text.